Paromomycin sulfate: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Paromomycin sulfate": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 21: | Line 21: | ||
{{CMG}} | {{CMG}} | ||
'''Paromomycin sulfate''' (brand name '''Humatin''') is a drug that fights intestinal infections such as [[cryptosporidiosis]] and amoeba infection, or [[amoebiasis]] and was developed as a therapeutic against [[visceral leishmaniasis]] by the [[Institute for OneWorld Health]]. Paromomycin was granted [[orphan drug]] status in 2005<ref>{{cite press release | '''Paromomycin sulfate''' (brand name '''Humatin''') is a drug that fights intestinal infections such as [[cryptosporidiosis]] and amoeba infection, or [[amoebiasis]] and was developed as a therapeutic against [[visceral leishmaniasis]] by the [[Institute for OneWorld Health]]. Paromomycin was granted [[orphan drug]] status in 2005<ref>{{cite press release | ||
| Line 52: | Line 52: | ||
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} | {{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} | ||
[[de:Paromomycin]] | [[de:Paromomycin]] | ||
{{jb1}} | {{jb1}} | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 14:47, 20 August 2012
| Error creating thumbnail: File missing | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral, intramuscular |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | None |
| Metabolism | None |
| Elimination half-life | ? |
| Excretion | Fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C23H47N5O18S |
| Molar mass | 615.629 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Paromomycin sulfate (brand name Humatin) is a drug that fights intestinal infections such as cryptosporidiosis and amoeba infection, or amoebiasis and was developed as a therapeutic against visceral leishmaniasis by the Institute for OneWorld Health. Paromomycin was granted orphan drug status in 2005[1] and was approved by the Drug Controller General of India in September 2006 for treatment of visceral leishmaniasis.[2]
Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA.[3]
References
- ↑ "Institute for OneWorld Health Drug Receives "Orphan" Designation From U.S. and European Regulatory Agencies" (Press release). Institute for OneWorld Health. 23 May 2005. Retrieved 2007-02-10.
- ↑ "New cure for deadly visceral leishmaniasis (kala-azar) approved by government of India" (Press release). Institute for OneWorld Health. 8 September 2006. Retrieved 2007-02-10.
- ↑ Vicens, Quentin (2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure. 9 (8): 647&ndash, 658. doi:10.1016/S0969-2126(01)00629-3. PMID 11587639. Retrieved 2007-02-10. Unknown parameter
|month=ignored (help); Unknown parameter|coauthors=ignored (help)
Template:Antidiarrheals, intestinal anti-inflammatory/anti-infective agents
de:Paromomycin Template:Jb1 Template:WH Template:WikiDoc Sources
Categories:
- Pages with script errors
- Pages with citations using unsupported parameters
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Antiprotozoal agents
- Aminoglycoside antibiotics
- Orphan drugs